1
|
Zhu J, Li Y, Li L, Wang J, Wang H, Hong W, Hao K, Xue Y, Chen B, Wang Z. A novel absorption spectrometric method, based on graphene nanomaterials, for detection of hepatocellular carcinoma-specific T lymphocyte cells. Int J Nanomedicine 2018; 13:5523-5536. [PMID: 30271145 PMCID: PMC6154735 DOI: 10.2147/ijn.s168574] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
Abstract
Introduction Detection of antigen-specific cytotoxic T lymphocytes (CTLs) is the foundation for understanding hepatocellular carcinoma immune pathology and hepatocellular carcinoma immunotherapy. However, the classical method for labeling CTLs, major histocompatibility complex (MHC)–peptide tetramer, has drawbacks and needs further improvement. Materials and methods Here, as a new detection probe, a graphene-based MHC–peptide multimer was developed for sensitively and selectively identifying hepatocellular carcinoma-specific T-cells. To assess its detection efficiency, reduced graphene oxide (RGO) was functionalized with hemin and streptavidin to prepare a functionalized HRGO–streptavidin complex. Biotinylated MHC–peptide monomer was subsequently constructed onto HRGO to generate a detection probe for CTL labeling. The number of T-cells was detected through the reaction between HRGO and tetramethylbenzidine. Results Using HRGO/MHC–peptide multimers, the number of T-cells was efficiently detected in both the induction system in vitro and in peripheral blood of patients. Conclusion HRGO/MHC-peptide multimers methodology has application prospects in the detection of antigen peptide-specific T cells.
Collapse
Affiliation(s)
- Jianmeng Zhu
- Department of Clinical Laboratory, Chun'an First People's Hospital (Zhejiang Provincial People's Hospital Chun'an Branch), Hangzhou, Zhejiang Province, China, ,
| | - Yiping Li
- Department of Clinical Laboratory, Chun'an First People's Hospital (Zhejiang Provincial People's Hospital Chun'an Branch), Hangzhou, Zhejiang Province, China, ,
| | - Lei Li
- Department of Pathophysiology, School of Basic Medical Science, Southern Medical University, Guangzhou, Zhejiang, China
| | - Jian Wang
- Department of Clinical Laboratory, Chun'an First People's Hospital (Zhejiang Provincial People's Hospital Chun'an Branch), Hangzhou, Zhejiang Province, China, ,
| | - Hongqin Wang
- Department of Clinical Laboratory, Chun'an First People's Hospital (Zhejiang Provincial People's Hospital Chun'an Branch), Hangzhou, Zhejiang Province, China, ,
| | - Wenzhong Hong
- Department of Clinical Laboratory, Chun'an First People's Hospital (Zhejiang Provincial People's Hospital Chun'an Branch), Hangzhou, Zhejiang Province, China, ,
| | - Ke Hao
- Department of Blood Transfusion, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, China, ,
| | - Yadan Xue
- Department of Blood Transfusion, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, China, ,
| | - Bingyu Chen
- Department of Clinical Laboratory, Chun'an First People's Hospital (Zhejiang Provincial People's Hospital Chun'an Branch), Hangzhou, Zhejiang Province, China, , .,Department of Blood Transfusion, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, China, ,
| | - Zhen Wang
- Department of Clinical Laboratory, Chun'an First People's Hospital (Zhejiang Provincial People's Hospital Chun'an Branch), Hangzhou, Zhejiang Province, China, , .,Department of Blood Transfusion, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, China, ,
| |
Collapse
|
2
|
Ciáurriz M, Beloki L, Zabalza A, Bandrés E, Mansilla C, Pérez-Valderrama E, Lachén M, Rodríguez-Calvillo M, Ramírez N, Olavarría E. Functional specific-T-cell expansion after first cytomegalovirus reactivation predicts viremia control in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis 2017; 19. [DOI: 10.1111/tid.12778] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2016] [Revised: 05/24/2017] [Accepted: 06/14/2017] [Indexed: 12/26/2022]
Affiliation(s)
- Miriam Ciáurriz
- Oncohematology Research Group; Navarrabiomed-Miguel Servet Foundation; IDISNA (Navarra's Health Research Institute); Pamplona Spain
| | - Lorea Beloki
- Oncohematology Research Group; Navarrabiomed-Miguel Servet Foundation; IDISNA (Navarra's Health Research Institute); Pamplona Spain
| | - Amaya Zabalza
- Oncohematology Research Group; Navarrabiomed-Miguel Servet Foundation; IDISNA (Navarra's Health Research Institute); Pamplona Spain
- Department of Haematology; Complejo Hospitalario de Navarra; Navarra Health Service; IDISNA; Pamplona Spain
| | - Eva Bandrés
- Oncohematology Research Group; Navarrabiomed-Miguel Servet Foundation; IDISNA (Navarra's Health Research Institute); Pamplona Spain
- Department of Haematology; Complejo Hospitalario de Navarra; Navarra Health Service; IDISNA; Pamplona Spain
- Immunology Unit; Complejo Hospitalario de Navarra; Navarra Health Service; IDISNA; Pamplona Spain
| | - Cristina Mansilla
- Oncohematology Research Group; Navarrabiomed-Miguel Servet Foundation; IDISNA (Navarra's Health Research Institute); Pamplona Spain
| | - Estela Pérez-Valderrama
- Oncohematology Research Group; Navarrabiomed-Miguel Servet Foundation; IDISNA (Navarra's Health Research Institute); Pamplona Spain
| | - Mercedes Lachén
- Oncohematology Research Group; Navarrabiomed-Miguel Servet Foundation; IDISNA (Navarra's Health Research Institute); Pamplona Spain
| | - Mercedes Rodríguez-Calvillo
- Oncohematology Research Group; Navarrabiomed-Miguel Servet Foundation; IDISNA (Navarra's Health Research Institute); Pamplona Spain
- Department of Haematology; Complejo Hospitalario de Navarra; Navarra Health Service; IDISNA; Pamplona Spain
| | - Natalia Ramírez
- Oncohematology Research Group; Navarrabiomed-Miguel Servet Foundation; IDISNA (Navarra's Health Research Institute); Pamplona Spain
| | - Eduardo Olavarría
- Oncohematology Research Group; Navarrabiomed-Miguel Servet Foundation; IDISNA (Navarra's Health Research Institute); Pamplona Spain
- Department of Haematology; Complejo Hospitalario de Navarra; Navarra Health Service; IDISNA; Pamplona Spain
- Imperial College Healthcare NHS Trust; Hammersmith Hospital; London UK
| |
Collapse
|
3
|
Ciáurriz M, Beloki L, Bandrés E, Mansilla C, Zabalza A, Pérez-Valderrama E, Lachén M, Ibáñez B, Olavarría E, Ramírez N. Streptamer technology allows accurate and specific detection of CMV-specific HLA-A*02 CD8 + T cells by flow cytometry. CYTOMETRY PART B-CLINICAL CYTOMETRY 2016; 92:153-160. [PMID: 26918565 DOI: 10.1002/cyto.b.21367] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/13/2015] [Revised: 01/15/2016] [Accepted: 02/23/2016] [Indexed: 12/25/2022]
Abstract
BACKGROUND Multimer technology is widely used to screen antigen-specific immune recovery after allogeneic hematopoietic stem cell transplantation (allo-HSCT) as it enables identification, enumeration, phenotypic characterization and isolation of virus-specific T-cells. Novel approaches of multimerization might improve on classical tetramer staining; however, their use as standard monitoring technique to quantify antigen-specific cells has not been validated yet. We have compared two of these available multimeric complexes: pentamer and streptamer to select the best strategy for the incorporation into clinical monitoring practice. METHODS CMVpp65495-503 -specific HLA-A*02:01 CD8+ T lymphocytes (CTLA *02:01 -CMVpp65495-503 ) were examined with pentamer and streptamer in peripheral blood cells of 77 healthy volunteers. Quantitative and qualitative analyses were performed to compare the precision and repeatability, sensitivity and accuracy and specificity of both technologies by flow cytometry. RESULTS Standard deviation for both techniques was less than 0.05 showing that they are repetitive and precise. Both techniques significantly correlated at high frequencies (rSpearman = 0.9422; P < 0.0001) but it was lost at lower levels (<1%) of CTLA *02:01 -CMVpp65495-503 (rSpearman = 0.3351; P = 0.1376). Streptamer is more accurate for the detection of CTLA *02:01 -CMVpp65495-503 providing significantly closer values to the theoretical ones (P < 0.0001) as pentamer binds unspecifically to a notable proportion of non-CMV-specific CD8+ T-cells. CONCLUSION Our results suggest that streptamer multimer provides precise, accurate and specific results to detect CTLA *02:01 -CMVpp65495-503 by flow cytometry. Streptamer multimer can be used not only for the monitoring of early CTLA *02:01 -CMVpp65495-503 reconstitution in immunosuppressed patients following allo-HSCT but also, in conjunction with its reversibility role, for the isolation of CTLA *02:01 -CMVpp65495-503 for its future use in adoptive immunotherapy. © 2016 International Clinical Cytometry Society.
Collapse
Affiliation(s)
- Miriam Ciáurriz
- Oncohematology Research Group, Navarrabiomed-Miguel Servet Foundation, IDISNA (Navarra's Health Research Institute), Pamplona, Spain
| | - Lorea Beloki
- Oncohematology Research Group, Navarrabiomed-Miguel Servet Foundation, IDISNA (Navarra's Health Research Institute), Pamplona, Spain
| | - Eva Bandrés
- Oncohematology Research Group, Navarrabiomed-Miguel Servet Foundation, IDISNA (Navarra's Health Research Institute), Pamplona, Spain.,Immunology Unit, Complejo Hospitalario de Navarra, Navarra Health Service, IDISNA, Pamplona, Spain.,Department of Haematology, Complejo Hospitalario de Navarra, Navarra Health Service, IDISNA, Pamplona, Spain
| | - Cristina Mansilla
- Oncohematology Research Group, Navarrabiomed-Miguel Servet Foundation, IDISNA (Navarra's Health Research Institute), Pamplona, Spain
| | - Amaya Zabalza
- Oncohematology Research Group, Navarrabiomed-Miguel Servet Foundation, IDISNA (Navarra's Health Research Institute), Pamplona, Spain
| | - Estela Pérez-Valderrama
- Oncohematology Research Group, Navarrabiomed-Miguel Servet Foundation, IDISNA (Navarra's Health Research Institute), Pamplona, Spain
| | - Mercedes Lachén
- Oncohematology Research Group, Navarrabiomed-Miguel Servet Foundation, IDISNA (Navarra's Health Research Institute), Pamplona, Spain
| | - Berta Ibáñez
- IDISNA, Red de Evaluación en Servicios Sanitarios y Enfermedades Cronicas (REDISSEC), Navarrabiomed-Fundación Miguel Servet, Navarra, Spain
| | - Eduardo Olavarría
- Oncohematology Research Group, Navarrabiomed-Miguel Servet Foundation, IDISNA (Navarra's Health Research Institute), Pamplona, Spain.,Department of Haematology, Complejo Hospitalario de Navarra, Navarra Health Service, IDISNA, Pamplona, Spain.,Hammersmith Hospital-Imperial College Healthcare NHS, London, United Kingdom
| | - Natalia Ramírez
- Oncohematology Research Group, Navarrabiomed-Miguel Servet Foundation, IDISNA (Navarra's Health Research Institute), Pamplona, Spain
| |
Collapse
|
4
|
Selection of adenovirus-specific and Epstein-Barr virus-specific T cells with major histocompatibility class I streptamers under Good Manufacturing Practice (GMP)-compliant conditions. Cytotherapy 2015; 17:989-1007. [PMID: 25866178 DOI: 10.1016/j.jcyt.2015.03.613] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2014] [Accepted: 03/11/2015] [Indexed: 01/21/2023]
Abstract
BACKGROUND AIMS Despite antiviral drug therapies, human adenovirus (HAdV), cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections still contribute substantially to transplant-related death of patients after hematopoietic stem cell transplantation. Earlier clinical studies demonstrated successful adoptive transfer of magnetically selected CMV-specific T cells via removable, and thus Good Manufacturing Practice-compliant, major histocompatibility class I streptamers. Thus, the primary focus of the present study was the selection of HAdV-streptamer+ T cells, although in three experiments, EBV-streptamer+ T cells were also selected. METHODS Cells from leukaphereses of healthy donors were prepared in large (1-6 × 10(9)) and small (25 × 10(6)) cell batches. Whereas the larger batch was directly labeled with streptamers to select HAdV- and/or EBV-specific T cells (large-scale), the smaller batch was used to generate in vitro virus-specific T-cell lines before streptamer labeling for streptamer selection (small-scale). Isolation of HAdV- and/or EBV-specific T cells was performed with the use of the CliniMACS device. RESULTS The purity of HAdV- and EBV-streptamer+ T cells among CD3+ cells, obtained from large-scale selection, was up to 6.7% and 44%, respectively. If HAdV- and EBV-streptamers were applied simultaneously, the purity of antigen-specific T cells reached up to 50.7%. A further increase in purity reaching up to 98% was achieved by small-scale selection of HAdV-specific T cells. All final products fulfilled the microbiological and chemical release criteria. Interferon-γ-response indicating functional activity was seen in 6 of 9 HAdV and 2 of 3 EBV large-scale selections and in 2 of 3 HAdV small-scale selections. CONCLUSIONS HAdV-streptamers were shown to be clinically feasible for few patients after the large-scale approach but for larger patient numbers if combined with EBV-streptamers or after the small-scale approach.
Collapse
|
5
|
Beloki L, Ciaurriz M, Mansilla C, Zabalza A, Perez-Valderrama E, Samuel ER, Lowdell MW, Ramirez N, Olavarria E. CMV-specific T cell isolation from G-CSF mobilized peripheral blood: depletion of myeloid progenitors eliminates non-specific binding of MHC-multimers. J Transl Med 2014; 12:317. [PMID: 25406933 PMCID: PMC4243324 DOI: 10.1186/s12967-014-0317-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2014] [Accepted: 11/04/2014] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND Cytomegalovirus (CMV)-specific T cell infusion to immunocompromised patients following allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) is able to induce a successful anti-viral response. These cells have classically been manufactured from steady-state apheresis samples collected from the donor in an additional harvest prior to G-CSF mobilization, treatment that induces hematopoietic stem cell (HSC) mobilization to the periphery. However, two closely-timed cellular collections are not usually available in the unrelated donor setting, which limits the accessibility of anti-viral cells for adoptive immunotherapy. CMV-specific cytotoxic T cell (CTL) manufacture from the same G-CSF mobilized donor stem cell harvest offers great regulatory advantages, but the isolation using MHC-multimers is hampered by the high non-specific binding to myeloid progenitors, which reduces the purity of the cellular product. METHODS In the present study we describe an easy and fast method based on plastic adherence to remove myeloid cell subsets from 11 G-CSF mobilized donor samples. CMV-specific CTLs were isolated from the non-adherent fraction using pentamers and purity and yield of the process were compared to products obtained from unmanipulated samples. RESULTS After the elimination of unwanted cell subtypes, non-specific binding of pentamers was notably reduced. Accordingly, following the isolation process the purity of the obtained cellular product was significantly improved. CONCLUSIONS G-CSF mobilized leukapheresis samples can successfully be used to isolate antigen-specific T cells with MHC-multimers to be adoptively transferred following allo-HSCT, widening the accessibility of this therapy in the unrelated donor setting. The combination of the clinically translatable plastic adherence process to the antigen-specific cell isolation using MHC-multimers improves the quality of the therapeutic cellular product, thereby reducing the clinical negative effects associated with undesired alloreactive cell infusion.
Collapse
Affiliation(s)
- Lorea Beloki
- Oncohematology Research Group, Navarrabiomed - Miguel Servet Foundation, Irunlarrea 3, 31008, Pamplona, Spain.
| | - Miriam Ciaurriz
- Oncohematology Research Group, Navarrabiomed - Miguel Servet Foundation, Irunlarrea 3, 31008, Pamplona, Spain.
| | - Cristina Mansilla
- Oncohematology Research Group, Navarrabiomed - Miguel Servet Foundation, Irunlarrea 3, 31008, Pamplona, Spain.
| | - Amaya Zabalza
- Oncohematology Research Group, Navarrabiomed - Miguel Servet Foundation, Irunlarrea 3, 31008, Pamplona, Spain.
| | - Estela Perez-Valderrama
- Oncohematology Research Group, Navarrabiomed - Miguel Servet Foundation, Irunlarrea 3, 31008, Pamplona, Spain.
| | - Edward R Samuel
- Department of Haematology, University College London Medical School, University College London, London, UK.
| | - Mark W Lowdell
- Department of Haematology, University College London Medical School, University College London, London, UK.
| | - Natalia Ramirez
- Oncohematology Research Group, Navarrabiomed - Miguel Servet Foundation, Irunlarrea 3, 31008, Pamplona, Spain.
| | - Eduardo Olavarria
- Oncohematology Research Group, Navarrabiomed - Miguel Servet Foundation, Irunlarrea 3, 31008, Pamplona, Spain. .,Department of Haematology, Complejo Hospitalario de Navarra, Navarra Health Service, Pamplona, Spain.
| |
Collapse
|